Climb Bio Inc
climbbio.comWhat Do They Do?
Develops antibody drug candidates for patients with immune-mediated diseases, including kidney and autoimmune disorders.
10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet…View ↗
Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells.…View ↗
In addition to budoprutug, we are developing CLYM116, a next-generation anti-APRIL (A PRoliferation-Inducing Ligand) mAb for the treatment…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
From neuroscience to immune diseases
The focus has moved from therapies for neuronal excitability disorders to antibody drug candidates for immune-mediated diseases. The latest pipeline centers on candidates for kidney and autoimmune disorders rather than the older report’s neuroscience programs.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet…View ↗
Our lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells.…View ↗
In addition to budoprutug, we are developing CLYM116, a next-generation anti-APRIL (A PRoliferation-Inducing Ligand) mAb for the treatment…View ↗
Who Do They Compete With?
Competes with Amgen, IASO Biotherapeutics, AbbVie, Cullinan Therapeutics, Zenas BioPharma, L. Hoffmann-La Roche, Merck &, Novartis, Bristol Myers Squibb, Cabaletta Bio, Kyverna Therapeutics, Nkarta, Otsuka Pharmaceutical, Jade Biosciences, Vertex Pharmaceuticals, Vera Therapeutics, Biogen, Takeda Pharmaceutical, Biohaven, and argenx
10-K for FY2025, filed Mar 5, 2026The competitive landscape for budoprutug includes multiple companies developing biologics and other modalities targeting CD19 for…View ↗
Loading...
